These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 18666366)
1. Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases. Chrysant SG Curr Clin Pharmacol; 2006 May; 1(2):139-46. PubMed ID: 18666366 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin receptor blocker selectivity at the AT1- and AT2-receptors: conceptual and clinical effects. Unger T; Sandmann S J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S6-9. PubMed ID: 17199211 [TBL] [Abstract][Full Text] [Related]
3. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. Chrysant SG J Clin Hypertens (Greenwich); 2007 Jun; 9(6):454-9. PubMed ID: 17541331 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Schmieder RE Am J Hypertens; 2005 May; 18(5 Pt 1):720-30. PubMed ID: 15882557 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor blockers: current status and future prospects. Ram CV Am J Med; 2008 Aug; 121(8):656-63. PubMed ID: 18691475 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Grothusen A; Divchev D; Luchtefeld M; Schieffer B Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847 [TBL] [Abstract][Full Text] [Related]
13. Clinical experience with angiotensin receptor blockers with particular reference to valsartan. Chrysant SG; Chrysant GS J Clin Hypertens (Greenwich); 2004 Aug; 6(8):445-51. PubMed ID: 15308883 [TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of angiotensin receptor blockers in different clinical settings. Verdecchia P; Angeli F; Repaci S; Mazzotta G; Gentile G; Reboldi G Vasc Health Risk Manag; 2009; 5():939-48. PubMed ID: 19997575 [TBL] [Abstract][Full Text] [Related]
15. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Thomas GN; Chan P; Tomlinson B Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636 [TBL] [Abstract][Full Text] [Related]
16. Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy. Ribeiro AB Curr Med Res Opin; 2006 Jan; 22(1):1-16. PubMed ID: 16393425 [TBL] [Abstract][Full Text] [Related]
17. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials. Flaa A; Aksnes TA; Strand A; Kjeldsen SE Expert Rev Cardiovasc Ther; 2007 May; 5(3):451-61. PubMed ID: 17489670 [TBL] [Abstract][Full Text] [Related]
18. The management of hypertension with angiotensin receptor blockers in special populations. Ferdinand KC; Taylor C Clin Cornerstone; 2009; 9 Suppl 3():S5-17. PubMed ID: 19409356 [TBL] [Abstract][Full Text] [Related]
19. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Sierra C; de la Sierra A Curr Opin Nephrol Hypertens; 2005 Sep; 14(5):435-41. PubMed ID: 16046901 [TBL] [Abstract][Full Text] [Related]